CA2097825A1 - Compositions synergiques de recepteurs solubles du complement et composes qui inhibent le complement ou suppriment l'activite immunitaire - Google Patents

Compositions synergiques de recepteurs solubles du complement et composes qui inhibent le complement ou suppriment l'activite immunitaire

Info

Publication number
CA2097825A1
CA2097825A1 CA002097825A CA2097825A CA2097825A1 CA 2097825 A1 CA2097825 A1 CA 2097825A1 CA 002097825 A CA002097825 A CA 002097825A CA 2097825 A CA2097825 A CA 2097825A CA 2097825 A1 CA2097825 A1 CA 2097825A1
Authority
CA
Canada
Prior art keywords
complement
group
compounds
composition
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002097825A
Other languages
English (en)
Inventor
Henry C. Marsh, Jr.
Patrick C. Kung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Cell Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2097825A1 publication Critical patent/CA2097825A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002097825A 1990-12-06 1991-12-06 Compositions synergiques de recepteurs solubles du complement et composes qui inhibent le complement ou suppriment l'activite immunitaire Abandoned CA2097825A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62387890A 1990-12-06 1990-12-06
US623,878 1990-12-06

Publications (1)

Publication Number Publication Date
CA2097825A1 true CA2097825A1 (fr) 1992-06-07

Family

ID=24499761

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002097825A Abandoned CA2097825A1 (fr) 1990-12-06 1991-12-06 Compositions synergiques de recepteurs solubles du complement et composes qui inhibent le complement ou suppriment l'activite immunitaire

Country Status (6)

Country Link
EP (1) EP0560929A1 (fr)
JP (1) JPH06503344A (fr)
KR (1) KR930703011A (fr)
AU (1) AU9149791A (fr)
CA (1) CA2097825A1 (fr)
WO (1) WO1992010205A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506247A (en) * 1988-04-15 1996-04-09 T Cell Sciences, Inc. Compounds that inhibit complement and/or suppress immune activity
US5173499A (en) * 1988-04-15 1992-12-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
US5366986A (en) * 1988-04-15 1994-11-22 T Cell Sciences, Inc. Compounds which inhibit complement and/or suppress immune activity
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
GB9301289D0 (en) * 1993-01-22 1993-03-17 Smithkline Beecham Plc Novel composition
ATE223230T1 (de) * 1993-02-12 2002-09-15 Avant Immunotherapeutics Inc Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
US5837499A (en) * 1993-12-06 1998-11-17 Ciba-Geigy Corporation DNA encoding C5A receptor antagonists having substantially no agonist activity and methods of expressing same
US5807824A (en) * 1993-12-06 1998-09-15 Ciba-Geigy Corporation C5A receptor antagonists having substantially no agonist activity
US5627264A (en) * 1994-03-03 1997-05-06 Alexion Pharmaceuticals, Inc. Chimeric complement inhibitor proteins
EP2815767A1 (fr) * 2004-05-14 2014-12-24 Alexion Pharmaceuticals, Inc. Prolongation de la survie d'un allogreffon par inhibition d'activité complémentaire
KR101650264B1 (ko) 2006-03-02 2016-08-22 알렉시온 파마슈티칼스, 인코포레이티드 보체 활성을 저해함으로써 동종이식편의 생존 연장
EP3124029A1 (fr) 2006-03-15 2017-02-01 Alexion Pharmaceuticals, Inc. Traitement de patients souffrant d'hémoglobinurie paroxystique nocturne par un inhibiteur de complément
AU2007293013B2 (en) 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
LT2894165T (lt) * 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
EP3011345B1 (fr) 2013-08-07 2017-10-04 Alexion Pharmaceuticals, Inc. Protéines de bio-marqueurs de syndrome hémolytique et urémique atypique
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727018A (en) * 1984-05-18 1988-02-23 Eichner Ronald D Immunoregulation of transplantable tissue
EP0309602B1 (fr) * 1987-09-30 1993-03-24 MUCOS EMULSIONSGESELLSCHAFT m.b.H. Utilisation d'enzymes catabolisantes pour la fabrication d'un médicament destiné au traitement du syndrome d'immunodéficience acquis (SIDA) et leurs stades préliminaires (LAS, ARC)
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds

Also Published As

Publication number Publication date
EP0560929A4 (fr) 1994-08-31
AU9149791A (en) 1992-07-08
KR930703011A (ko) 1993-11-29
JPH06503344A (ja) 1994-04-14
WO1992010205A1 (fr) 1992-06-25
EP0560929A1 (fr) 1993-09-22

Similar Documents

Publication Publication Date Title
CA2097825A1 (fr) Compositions synergiques de recepteurs solubles du complement et composes qui inhibent le complement ou suppriment l'activite immunitaire
KR100596109B1 (ko) Ｃｄ11/ｃｄ18 부착 수용체 매개 질환 치료용 길항제
AU2002248142B8 (en) LFA-1 antagonist compounds
CZ369896A3 (en) Inhibitors of enzyme converting interleukin-1beta, process of their preparation and pharmaceutical compositions containing thereof
JPH05504762A (ja) 抗血栓性ペプチド及び偽ペプチド
JP2001517245A (ja) 細胞接着阻害薬としてのビアリールアルカン酸類
EP0984981A1 (fr) Derives anti-inflammatoires de tyrosine
AU663066B2 (en) Compounds that inhibit complement and/or suppress immune activity
AU5755499A (en) Fc receptor modulators and uses thereof
US5808109A (en) Compounds that inhibit complement and/or suppress immune activity
JPH02256657A (ja) Ｎ―置換アミド
KR20020067702A (ko) 질소 함유 5원환 화합물 및 이러한 화합물을 유효성분으로서 함유하는 약제
JP2011525486A (ja) 活動亢進性免疫系を治療するためのシクロリグナンの使用
US5173499A (en) Compounds which inhibit complement and/or suppress immune activity
KR20020058078A (ko) 옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제
RU2756055C2 (ru) Гетероциклические соединения и их применение
JPH06271533A (ja) 免疫抑制剤としての新規なアミノメチレン誘導体
WO1994011400A1 (fr) Peptides de icam-2 et icam-1 chez l'homme et leurs analogues s'utilisant en therapie et diagnostic
CZ222498A3 (cs) Inhibitor kolagenázy na bázi kyseliny hydroxamové, farmaceutický prostředek s jeho obsahem, způsob jeho přípravy a použití
WO2007132179A2 (fr) Agents thérapeutiques
JPH0745453B2 (ja) アシルアミノヒドロキシアルカノイルアミノおよびイミノ酸並びにエステル類
KR100856767B1 (ko) 인터류킨-1 베타 전환효소의 억제제
Bhat et al. Immunology in drug research
JPS61118352A (ja) アミノ酸エステルおよびアミドレニン抑制剤

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 19960606